The combination therapy could not only improve ORR and PFS, but also potentially improve OS in patients with ASPS due to the typical molecular mismatch repair deficiency and aberrant upregulation of HIF1α and VEGF (32). This evidence concerns the gene HIF1A and alveolar soft part sarcoma.